Teva reported that its investigational antibody TEV’408 succeeded in a mid-stage celiac disease gluten challenge study by significantly reducing intestinal damage. In the trial, participants ate gluten daily after receiving the drug, and TEV’408 showed statistically significant and clinically meaningful protection compared with placebo over eight weeks. Teva positioned the data as advancing “pipeline-in-a-product potential,” while also referencing earlier work in vitiligo as supportive evidence for broader development. Teva said analyses from an ongoing Phase 2a study are underway, with additional results expected to be shared at future scientific meetings. With no FDA-approved therapies currently for celiac disease, the company’s readout adds pressure to the competitive race to deliver the first approved treatment that can prevent gluten-induced injury.